Skip to main content
Premium Trial:

Request an Annual Quote

Center for Molecular Medicine to Provide Genotyping Services for COG Leukemia Study

NEW YORK (GenomeWeb News) - The Center for Molecular Medicine will provide genotyping and analysis services to the Children’s Oncology Group to support a study of genetic abnormalities and their association with response to therapies for treatment of childhood leukemia, CMM said today.
 
CMM, based in Grand Rapids, Mich., said that in the first phase of the study it will analyze up to 2,200 matched samples of DNA from pediatric leukemia patients’ blood samples and their leukemic blasts. The aim is to identify and catalog genetic variations that COG can use in its efforts to develop improved diagnostics and therapeutics for childhood leukemia.
 
CMM will “identify and catalog about a million key SNPs” in these samples, said CMM executive director Daniel Farkas.
 
CMM said it will begin testing samples this month, and that Phase I may be completed by spring.
 
COG and CMM are also “working together to identify sources of funding to expand the study to six to eight thousand more specimens,” CMM said in a statement.
 
Financial terms of the agreement were not released.
 
CMM is a clinical diagnostics laboratory formed last year as a joint venture between Spectrum Health and Van Andel Institute.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.